Affitope AD 02

Drug Profile

Affitope AD 02

Alternative Names: AD-02; AD-2; Affitope AD02; Alzheimer AD02

Latest Information Update: 03 Sep 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AFFiRiS
  • Class Alzheimer vaccines; Subunit vaccines
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 23 Jun 2014 Discontinued - Phase-II for Alzheimer's disease in Austria, Germany, France, Croatia, Czech Republic and Slovakia (SC)
  • 05 Jun 2014 Efficacy and adverse events data from a phase II trial in Alzheimer's disease (early disease) released by AFFiRiS
  • 01 Dec 2013 AFFiRiS completes a phase II trial in Alzheimer's disease in Austria, Croatia, Czech Republic, France, Germany, and Slovakia (NCT01117818)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top